Trastuzumab combined with trimodality treatment does not improve outcomes for patients

May 29, 2020

Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma. These results were recently, orally presented during the virtual Annual Meeting of the American Society for Clinical Oncology.

The Phase III NRG-RTOG 1010 trial evaluated 203 HER2 positive patients with a median follow up of 5 years. The primary aim of the trial was to determine if the addition of trastuzumab could improve DFS when combined with trimodality treatment of chemotherapy, radiotherapy, and surgery for patients who have newly diagnosed esophageal cancer with HER2 overexpression. Patients on the trial had stage T1N1-2, T2-3N0-2 adenocarcinoma of the esophagus involving mid, distal, or esophagogastric junction and up to 5 centimeters of the stomach.

Trial participants were randomly assigned to trimodality standard of care with or without trastuzumab.Participants on the standard of care arm received chemotherapy, consisting of paclitaxel and carboplatin weekly, for 6 weeks with radiotherapy (CXRT) then followed by surgery. Participants on the experimental treatment arm received weekly trastuzumab during CXRT and then every 3 weeks following surgery for 13 treatments.

Patients were evaluated for disease every 4 months for 2 years and then annually. DFS rates (95% CI) for patients on the CXRT plus trastuzumab (CXRT+T) treatment arm were 41.8% (31.8%, 51.7%) at 2 years, 34.3% (24.7%, 43.9%) at 3 years, and 33.1% (23.6%, 42.7%) at 4 years. DFS for patients on the CXRT alone arm were 40% (30.0%, 49.9%) at 2 years, 33.4% (23.8%, 43.0%) at 3 years, and 30.1% (20.7%, 39.4%)at 4 years, log-rank p=0.85. The median DFS time DFS in the CXRT+T arm was 19.6 months compared to 14.2 months in the CXRT alone arm. The hazard ratio (95% CI) comparing the DFS of CXRT+T arm to the CXRT alone arm was 0.97 (0.69, 1.36) and there were no statistically significant differences in treatment-related toxicity between arms.

"The strength of the National Cancer Institute's National Clinical Trials Network system was highlighted in this trial, as accrual of this HER2 overexpressing population was successfully completed as projected, allowing this important question to be answered. We will be performing genomic analysis to determine if there was a subset of patients who may still benefit from from the addition of trastuzumab to trimodality therapy in HER2 over expressing esophageal cancer," stated Howard Safran, MD, of The Rhode Island Hospital and Brown University, the lead author of the NRG-RTOG 1010 abstract.
This project was supported by grants U10CA180868 (NRG Oncology Operations), UG1CA189867 (NRG Oncology NCORP), U10CA180822 (NRG Oncology SDMC) from the National Cancer Institute (NCI), part of the National Institutes of Health and Genentech. NRG-RTOG 1010 was sponsored by NCI and Genentech provided trastuzumab to support the study through a Collaborative Research and Development Agreement with NCI.


Safran HP, Winter KA, Wigle D, DiPetrillo TA, Haddock MG, Hong TS, Leichman LP, Lakshmi R, Kachnic LA, Seaward S, Mamon H, Diaz Pardo DA, Anderson CM, Shen X, Sharma AK, Katz AW, Salo J, Leonard KL, Crane CH. Trastuzumab With Trimodality Treatment For Esophageal Adenocarcinoma with HER2 Overexpression: NRG Oncology/RTOG 1010. Abstract presented at the virtual Annual Meeting of the American Society of Clinical Oncology (ASCO).

About NRG Oncology

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology's extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trials Network.

NRG Oncology

Related Trastuzumab Articles from Brightsurf:

Opening an autophagy window as the apoptosis door starts to close
Tokyo Medical and Dental University (TMDU) researchers have successfully attached the cancer cell-targeting antibody Trastuzumab to a previously reported supermolecule that induces autophagic cell death.

Yale Cancer Center study validates combination therapy for aggressive endometrial cancer
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.

Oncotarget: Second line trastuzumab emtansine following horizontal dual blockade
Volume 11, Issue 22 of Oncotarget reported that despite relevant medical advancements, metastatic breast cancer remains an incurable disease.

Trastuzumab combined with trimodality treatment does not improve outcomes for patients
Results of the NRG Oncology clinical trial RTOG 1010 indicated that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient with HER2 overexpressing local and locally advanced esophageal adenocarcinoma.

Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS
The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.

Trastuzumab deruxtecan shows early promise in patients with non-breast/gastric cancers
A HER2-targeted antibody-drug conjugate, fam-trastuzumab deruxtecan-nxki (Enhertu), showed signs of clinical activity in multiple non-breast/non-gastric cancer types, according to results from a phase I study.

Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial.

Biosimilar for HER2+ breast cancer: Overall response rate matches reference trastuzumab
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase III study reported at the ESMO Asia 2019 Congress.

Two-in-one drug combining Herceptin with chemotherapy keeps women's breast cancers at bay
Guiding chemotherapy to a tumor by attaching it to the antibody-based target drug Herceptin (trastuzumab) is effective at treating women with breast cancer who have no other treatment options, a new clinical trial shows.

Simple and fast method for radiolabelling antibodies against breast cancer
Radioactive antibodies that target cancer cells are used for medical diagnostics with PET imaging or for targeted radioimmunotherapy.

Read More: Trastuzumab News and Trastuzumab Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to